Nuformix PLC Board Changes (0002U)
28 July 2022 - 4:01PM
UK Regulatory
TIDMNFX
RNS Number : 0002U
Nuformix PLC
28 July 2022
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK
LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS
(SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.
28 July 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Board Changes
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce the appointment of Dr Daniel
("Dan") Gooding as an Executive Director of the Company with effect
from 1 August 2022.
Dr Gooding was a co-founder of Nuformix and the Company's CEO
until June 2020. He instigated the Company's NXP002 programme as an
inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis
(IPF) and has been acting as a consultant to the Company since
March 2022. He has over 22 years' experience in commercialisation
and business development within the pharmaceutical industry, having
received his PhD in chemistry from Leeds University. Dan began his
career in commercial roles with pharmaceutical excipients companies
including FMC and Dow Corning. At Accelrys Ltd, Dan was responsible
for sales across the UK and Southern Europe, leading business
development within the emerging nanotechnology, drug delivery and
formulation sectors, achieving licensing deals with Johnson &
Johnson and AstraZeneca. Since June 2020, Dan has remained close to
the fields of fibrosis, oncology and drug repurposing. Dan
supported the management team of Qureight Limited in securing
funding and establishing this Cambridge-based start-up, which
develops AI-based image processing methods in measuring disease
progression and drug response for patients with fibrotic lung
diseases including IPF. Dan has also cofounded TRx Biosciences, a
company developing new oral therapies using a novel targeted
delivery technology to improve treatment of various cancers and CNS
diseases.
In addition, Dr Julian Gilbert, currently a Non-executive
Director of the Company has been appointed to the role of
Non-executive Chairman. Following these changes the board of the
Company will comprise Dr Julian Gilbert, Non-executive Chairman, Dr
Dan Gooding, Executive Director, and Maddy Kennedy, Non-executive
Director.
Other than as set out in this announcement there are no further
disclosures required in respect of Dr Daniel John Gooding under
paragraph 9.6.13 of the Listing Rules.
Commenting, Dr Julian Gilbert, Non-executive Chairman of
Nuformix, said: "I am pleased that Dan has agreed to join the board
as an Executive Director. He brings significant history with
Nuformix and experience to the table which will help facilitate the
progression of our assets, and in particular our NXP002 programme.
I believe that we now have a board and management structure
appropriate for the Company's needs in order to optimise value from
its assets while maintaining tight control of costs. I look forward
to providing further updates in due course as we progress."
Enquiries:
Nuformix plc
Dr Julian Gilbert, Non-executive Via IFC Advisory
Chairman
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABDLLLLDLBBBX
(END) Dow Jones Newswires
July 28, 2022 02:01 ET (06:01 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024